ROMA (ITALPRESS) – Angelini Pharma S.p.A., international pharmaceutical company part of the Angelini Industries Group, and Catalyst Pharmaceuticals, biopharmaceutical company in commercial phase focused on in-licensing, the development and marketing of innovative drugs for patients suffering from rare and difficult diseases, have announced today a definitive agreement in virtue of which Angelini Pharma has committed itself to circulation.
The operation was unanimously approved by the Boards of Directors of both companies and is expected to be closed during the third quarter of 2026.
The operation announced today represents a turning point in the transformational path of Angelini Pharma, a group that boasts over 100 years of history, chaired by Thea Paola Angelini, the fourth generation of the Angelini family, and led by Sergio Marullo di Condojanni CEO of Angelini Pharma.
The operation is carried out with the participation of funds managed by Blackstone and selected international partners, and will be funded with the support of BNP Paribas, acting as the Unique Global Coordinator and Subscriptor of the financing package. Founded in 2002 and listed at Nasdaq since 2006, Catalyst has built a solid portfolio of products focusing on the treatment of rare neuromuscular and neurological diseases: Firdapse (amifampridine), the only treatment based on clinical evidence approved by the US Food and Drug Administration (FDA) for Lambert-Eaton Mysthenic Syndrome (LEMS) in patients aged six years; Agamree (vorolone), an innovative corticosteroid approved by the FDA in 2023 for the treatment of Duchenne’s muscle dystrophy (DMD) in patients aged 2 or over; and Fycompa (perampanel), an antiepileptic drug approved for the treatment of focal onset crises and primary tonic-clonic crises, whose rights for the US market were acquired by 23.
Following the completion of the acquisition, Angelini Pharma intends to integrate Catalyst Pharmaceuticals’ portfolio and solid commercial infrastructure with its expertise and products in Brain Health to develop a new generation therapeutic platform in Rare Diseases.
This operation reinforces the commitment initiated by Angelini Pharma in recent years through products such as Ontozry® and high-profile scientific collaborations. Catalyst’s portfolio will significantly strengthen the company’s strategic objectives by consolidating its presence in the United States within a balanced growth plan, which aims to develop the North American market without sacrificing the strengthening of core business in Europe. The industrial presence in Italy will remain a strategic asset for Angelini Pharma, a productive and scientific reference of value in the context of its global operations.
Sergio Marullo di Condojanni, CEO of Angelini Pharma, said: “Five years ago we started a profound transformation of Angelini Pharma — organizational, scientific and strategic — with the aim of building a company capable of competing globally. On the one hand, continuing to invest in our traditional portfolio, on the other, focusing on the care of the pathologies of the central nervous system, with the goal of responding to a need that is unfortunately growing so We invested in innovation through the development of a pipeline of high value assets, also through collaboration agreements with leading partners like Blackstone Life Sciences in GRIN Therapeutics. Today we make a new significant step with the acquisition of Catalyst Pharmaceuticals that will make Angelini Pharma a leading global player in neurological Rare Diseases. Entry into the US market will allow us to acquire the scale and skills necessary to continue on this path. Patient care is always at the heart of our vision, and we continue to look forward with strong determination of a clear strategy and the will to continue to grow globally. We are proud of an operation that once again demonstrates the dynamism of the Italian pharmaceutical industry.”.
Rich Daly, Chairman and CEO of Catalyst Pharmaceuticals, commented: “This is a crucial moment of great transformation for Catalyst, for our team and for the patients we serve. By combining our unique skills in rare diseases with the proven global presence of Angelini Pharma, we will create a platform for rare diseases more solid, scalable and structured, to expand access to therapies that can change the lives of patients worldwide. For shareholders, this transaction generates an immediate and certain value in terms of liquidity, thanks to a significant premium. We are proud of the extraordinary foundations our team has built and we are sure that, together with Angelini Pharma, we can improve patient support, accelerate innovation and continue to generate sustainable value in the long term for all stakeholders.”.
– Press office photos Sec –
(ITALPRESS).
